环境响应的智能化递药系统在肿瘤靶向治疗研究的应用

doi:10.5246/jcps.2015.01.001

中国药学(英文版) ›› 2015, Vol. 24 ›› Issue (1): 1-11.DOI: 10.5246/jcps.2015.01.001

• 【综述】 • 下一篇

环境响应的智能化递药系统在肿瘤靶向治疗研究的应用

彭春梅, 沈洁, 陆伟跃^*

复旦大学药学院智能化递药教育部重点实验室, 上海 201203

收稿日期:2014-07-08 修回日期:2014-07-24 出版日期:2015-01-15 发布日期:2014-07-28
通讯作者: Tel.: 86-13916210734
作者简介:陆伟跃, 复旦大学药剂学教授、博士生导师。本科就读于上海第一医学院化学制药专业, 师从侯惠民院士, 获得上海医药工业研究院药剂学博士学位。2011年起任智能化递药教育部重点实验室主任, 2013年起任国家重大科学研究计划项目首席科学家。现兼任中国药学会药剂专委会副主任委员、中国医药工业科研开发促进会理事、中国抗癌协会纳米肿瘤学专委会常务委员、上海市药学会常务理事及药剂专委会主任委员, 《中华医学百科全书》药学类药剂学卷副主编, Drug Delivery and Translational Research、Asian Journal of Pharmaceutical Sciences、《中国药学》(英文版)、《药学学报》、《中国药学》、《中国医药工业杂志》等杂志编委。主要从事药物靶向策略及递药系统研究, 在脑、淋巴系统及其肿瘤靶向递药等研究方面主持国家及省部级课题20余项。国内外发明专利授权20项, 开发新药4项, 发表SCI论文80余篇, 副主译出版《制剂技术百科全书》1部。曾获全国百篇优秀博士学位论文指导教师、上海市育才奖, 宝钢优秀教师奖, 徐光启科技奖章金奖, 中国药学会科学技术二等奖等。
基金资助:
National Basic Research Program of China (Grant No. 973 Program, 2013CB932500), National Natural Science Foundation of China (Grant No. 81273458) and Specialized Research Fund for the Doctoral Program of Higher Education (Grant No. 20110071130011).

Environment-responsive drug delivery systems for targeted cancer therapy

Chunmei Peng, Jie Shen, Weiyue Lu^*

Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Department of Pharmaceutics, and School of Pharmacy, Fudan University, Shanghai 201203, China

Received:2014-07-08 Revised:2014-07-24 Online:2015-01-15 Published:2014-07-28
Contact: Tel.: 86-13916210734
About author:Weiyue Lu, Ph.D. is a Professor of pharmaceutics, School of Pharmacy at Fudan University. Professor Lu obtained his B.S. degree in Medicinal Chemistry from Department of Pharmacy, Shanghai First Medical College (Now School of Pharmacy, Fudan University) in 1982, and his Ph.D. degree in pharmaceutics from Shanghai Institute of Pharmaceutical Industry. He also serves as the director of Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, China, Associate Director of the Pharmaceutics Committee of Chinese Pharmaceutical Association (CPA), Director of the Pharmaceutics Committee of Shanghai Pharmaceutical Association, Council member of Chinese Pharmaceutical Industry Research and Developmen Association and also a member of standing committee, Nano-oncology Committee of Chinese Anti-cancer Association, associate chief editor for Pharmaceutical volume in Pharmaceutical Science Part of Encyclopendia of Chinese Medicine, member of Editorial Board for Drug Delivery and Translational Research, Asian Journal of Pharmaceutical Sciences, Acta Pharmaceutica Sinica, Chinese Journal of Pharmaceuticals, Journal of Chinese Pharmaceutical Sciences. Professor Lu’s research focuses on brain, lymphatic system and its tumor targeting strategy and drug delivery system. Since 2000, he has published 80 peer-reviewed papers and holds 20 patents. He has received the National 100 Excellent Doctoral Dissertation Award (Advisor) in 2012 and 2013. At present, he has host a project on the National Basic Research Program (973) in 2013. He has ever won Shanghai YuCai Award, “Prize for Excellent Teacher” funded by Baosteel Fellowship, Gold Medal of “Xu Guang Qi Science and Technology Medal” and the second prize of scientific and technological progress award of Chinese Pharmaceutical Association.
Supported by:
National Basic Research Program of China (Grant No. 973 Program, 2013CB932500), National Natural Science Foundation of China (Grant No. 81273458) and Specialized Research Fund for the Doctoral Program of Higher Education (Grant No. 20110071130011).

摘要/Abstract

摘要：

环境响应的智能化递药系统可对肿瘤组织特殊生理环境及体外环境变化而发生相应变化, 特异地靶向分布于肿瘤组织或在肿瘤组织的特殊生理环境下释放药物, 从而可有效改善并提高抗癌药物对肿瘤靶向治疗效果, 降低药物毒副作用, 已成为近年来肿瘤靶向治疗研究领域的热点之一。本文综述了环境响应的智能化递药系统的靶向机理及其在肿瘤靶向治疗中的应用, 以期为新型肿瘤靶向递药系统的开发及其对肿瘤的治疗提供参考。

关键词: 肿瘤, 环境响应, 靶向, 智能化递药系统

Abstract:

In order to deliver and/or release anti-cancer therapeutics at the tumor sites, novel environment-responsive drug deliverysystems are designed to specifically respond to tumor microenvironment (such as low pH and hypoxia). Due to their extraordinary advantages, these environment-responsive drug delivery systems can improve antitumor efficacy, and most importantly, they can decrease toxicity associated with the anti-cancer therapeutics. This review highlights different mechanisms of environment-responsive drug delivery systems and their applications for targeted cancer therapy.

Key words: Cancer, Environment-responsive, Target, Smart drug delivery systems

中图分类号:

R965

Supporting:

彭春梅, 沈洁, 陆伟跃. 环境响应的智能化递药系统在肿瘤靶向治疗研究的应用[J]. 中国药学(英文版), 2015, 24(1): 1-11.

Chunmei Peng, Jie Shen, Weiyue Lu. Environment-responsive drug delivery systems for targeted cancer therapy[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(1): 1-11.

参考文献

[1] Van Meerbeeck, J.P.; Scherpereel, A.; Surmont ,V.F.; Baas, P. Crit. Rev. Oncol. Hematol . 2011, 78, 92-111.

[2] Kim, J.H.; Kim, H.S.; Kwon, J.H.; Park, S.; Kim, H,Y.; Jung, J.Y. Lung Cancer. 2009, 63, 405-409.

[3] Islam, T.; Josephson, L. Cancer Biomark. 2009, 5, 99-107.

[4] Das, M.; Mohanty, C.; Sahoo, S.K. Expert Opin. Drug Deliv. 2009, 6, 285-304.

[5] Sun, Y.; Wang, C. Acta Pharm. Sin. 2008, 43, 992-996.

[6] Ojugo, A.S.; McSheehy, P.M.; McIntyre, D.J.; McCoy, C.; Stubbs, M.; Leach, M.O. NMR Biomed. 1999, 12, 495-504.

[7] Stubbs, M.; McSheehy, P.M.; Griffiths, J.R.; Bashford, C.L. Mol. Med. Today. 2000, 6, 15-19.

[8] Lee, R.J.; Wang, S.; Low, P.S. Biochim. Biophys Acta. 1996, 1312, 237-242.

[9] Leriche, G.; Chisholm, L.; Wagner, A. Bioorg. Med. Chem. 2012, 20, 571-582.

[10] Jiang, S.; Yao, Y.; Nie, Y.; Yang, J.; Yang, J. J. Colloid Interface Sci. 2011, 364, 264-271.

[11] Alani, A.W.; Bae, Y.; Rao, D.A.; Kwon, G.S. Biomaterials. 2010, 31, 1765-1772.

[12] Zhao, B.X.; Zhao, Y.; Huang, Y.; Luo, L.M.; Song, P.; Wang, X. Biomaterials. 2012, 33, 2508-2520.

[13] Wang, C.H.; Wang, C.H.; Hsiue, G.H. J. Control. Release. 2005, 108, 140-149.

[14] Gao, G.H.; Lee, J.W.; Nguyen, M.K.; Im, G.H.; Yang, J.; Heo, H. J. Control. Release. 2011, 155, 11-17.

[15] Oh, K.T.; Kim, D.; You, H.H.; Ahn, Y.S.; Lee, E.S. Int. J. Pharm. 2009, 376, 134-140.

[16] Lu, C.; Xing, M.M.; Zhong, W. Nanomedicine. 2011, 7, 80-87.

[17] Wang, X.; Wu, G.; Lu, C.; Zhao, W.; Wang, Y.; Fan, Y. Eur. J. Pharm. Sci. 2012, 47, 256-264.

[18] Du, C.; Deng, D.; Shan, L.; Wan, S.; Cao, J.; Tian, J. Biomaterials. 2013, 34, 3087-3097.

[19] Tang, R.; Ji, W.; Panus, D.; Palumbo, R.N.; Wang, C. J. Control. Release. 2011, 151, 18-27.

[20] Hu, F.Q.; Zhang, Y.Y.; You, J.; Yuan, H.; Du, Y.Z. Mol. Pharm. 2012, 9, 2469-2478.

[21] Jin, Y.H.; Hu, H.Y.; Qiao, M.X.; Zhu, J.; Qi, J.W.; Hu, C.J. Colloids Surf. B Biointerfaces. 2012, 94, 184-191.

[22] Niu, J.; Su, Z.; Xiao, Y.; Huang, A.; Li, H.; Bao, X. Eur. J. Pharm. Sci. 2012, 45, 216-226.

[23] Goncalves, M.; Figueira, P.; Maciel, D.; Rodrigues, J.; Qu, X.; Liu, C. Acta Biomater. 2014, 10, 300-307.

[24] Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. J. Control. Release. 2008, 126, 187-204.

[25] Song, N.; Liu, W.; Tu, Q.; Liu, R.; Zhang, Y.; Wang, J. Colloids Surf. B Biointerfaces. 2011, 87, 454-463.

[26] Koo, A.N.; Min, K.H.; Lee, H.J.; Lee, S.U.; Kim, K.; Kwon, I.C. Biomaterials. 2012, 33, 1489-1499.

[27] Manickam, D.S.; Li, J.; Putt, D.A.; Zhou, Q.H.; Wu, C.; Lash, L.H. J. Control. Release. 2010, 141, 77-84.

[28] He, Y.; Nie, Y.; Xie, L.; Song, H.; Gu, Z. Biomaterials. 2014, 35, 1657-1666.

[29] Brisson, L.; Reshkin, S.J.; Gore, J.; Roger, S. Eur. J. Cell Biol. 2012, 91, 847-860.

[30] Liang, L.; Lin, S.W.; Dai, W.; Lu, J.K.; Yang, T.Y.; Xiang, Y. J. Control Release. 2012, 160, 618-629.

[31] Zhu, L.; Perche, F.; Wang, T.; Torchilin, V.P. Biomaterials. 2014, 35, 4213-4122.

[32] Lee, G.Y.; Park, K.; Kim, S.Y.; Byun, Y. Eur. J. Pharm. Biopharm. 2007, 67, 646-654.

[33] Huang, S.; Shao, K.; Kuang, Y.; Liu, Y.; Li, J.; An, S. Biomaterials. 2013, 34, 5294-5302.

[34] Harada, S.; Ehara, S.; Ishii, K.; Sato, T.; Koka, M.; Kamiya, T. Nuclear Instruments & Methods in Physics Research Section B-Beam Interactions with Materials and Atoms. 2014, 318, 173-177.

[35] Hossann, M.; Wiggenhorn, M.; Schwerdt, A.; Wachholz, K.; Teichert, N.; Eibl, H. Biochim. Biophys. Acta. 2007, 1768, 2491-2499.

[36] Kim, M.S.; Lee, D.W.; Park, K.; Park, S.J.; Choi, E.J.; Park, E.S. Colloids Surf. B Biointerfaces. 2014, 116, 17-25.

[37] Lin, Z.Q.; Gao, W.; Hu, H.X.; Ma, K.; He, B.; Dai, W.B. J. Control. Release. 2014, 174, 161-170.

[38] Yoon, H.Y.; Saravanakumar, G.; Heo, R.; Choi, S.H.; Song, I.C.; Han, M.H. J. Control. Release. 2012, 160, 692-698.

[39] Tietze, R.; Lyer, S.; Durr, S.; Struffert, T.; Engelhorn, T.; Schwarz, M. Nanomedicine-Nanotechnol. Biol. Med. 2013, 9, 961-971.

[40] Fomina, N.; Sankaranarayanan, J.; Almutairi, A. Adv. Drug Deliv. Rev. 2012, 64, 1005-1020.

[41] Cho, Y.I.; Park, S.; Jeong, S.Y.; Yoo, H.S. Eur. J. Pharm. Biopharm. 2009, 73, 59-65.

[42] Yin, T.H.; Wang, P.; Li, J.G.; Zheng, R.Q.; Zheng, B.W.; Cheng, D. Biomaterials. 2013, 34, 4532-4543.

[43] Huang, S.; Shao, K.; Liu, Y.; Kuang, Y.; Li, J.; An, S. ACS Nano. 2013, 7, 2860-2871.

[44] Pradhan, P.; Giri, J.; Rieken, F.; Koch, C.; Mykhaylyk, O.; Doblinger, M. J. Control. Release. 2010, 142, 108-121.

[45] Wen, H.; Guo, J.; Chang, B.; Yang, W. Eur. J. Pharm. Biopharm. 2013, 84, 91-98.

[46] Yu, S.F.; Wu, G.L.; Gu, X.; Wang, J.J.; Wang, Y.N.; Gao, H. Colloids Surf. B Biointerfaces. 2013, 103, 15-22.

[47] Shi, J.J.; Liu, Y.; Wang, L.; Gao, J.; Zhang, J.; Yu, X.Y. Acta Biomaterialia. 2014, 10, 1280-1291.

[48] Qiao, Z.Y.; Zhang, R.; Du, F.S.; Liang, D.H.; Li, Z.C. J. Control. Release. 2011, 152, 57-66.

[49] Grull, H.; Langereis, S. J. Control. Release. 2012, 161, 317-327.

[50] Ranjan, A.; Jacobs, G.C.; Woods, D.L. J. Control. Release. 2012, 158, 487-494.

[51] de Smet, M.; Langereis, S.; van den Bosch, S.; Bitter, K.; Hijnen, N.M.; Heijman, E. J. Control. Release. 2013, 169, 82-90.

环境响应的智能化递药系统在肿瘤靶向治疗研究的应用

Environment-responsive drug delivery systems for targeted cancer therapy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吕雯, 付颖. Graves眼病的免疫靶向治疗的研究进展[J]. 中国药学(英文版), 2023, 32(8): 616-625.
[2]	陈培杰, 张云天. PTP1B抑制肝纤维化逆转期TRAIL诱导的肝星状细胞凋亡[J]. 中国药学(英文版), 2023, 32(11): 867-880.
[3]	李楷, 唐冰洁, 柴新龙, 平洋, 王丽红, 苏瑾. 唾液酸功能化靶向给药系统: 与唾液酸结合免疫球蛋白样凝集素或选择素受体结合的肿瘤和炎症治疗进展[J]. 中国药学(英文版), 2023, 32(10): 773-795.
[4]	刘良裕, 杨宇珂, 杜肖, 吴桐, 王建农. 白英中三个未被报道的甾体糖苷生物碱及其抗肿瘤活性[J]. 中国药学(英文版), 2022, 31(3): 192-201.
[5]	许士琪, 朱礼岩, 郝超, 刘文倩, 陈成龙, 陈泳怡, 刘爱芹. 一种新型含氨基酸基团替加氟前药的合成及其抗肿瘤活性评价[J]. 中国药学(英文版), 2021, 30(9): 743-753.
[6]	黄聪, 吴霭琳, 海沙尔江·吾守尔, 徐子悦, 张逸晨, 管晓东, 史录文. 中国浙江省级医保报销对于靶向抗肿瘤药使用的影响: 一项带对照的间断时间序列分析[J]. 中国药学(英文版), 2021, 30(7): 590-597.
[7]	汪子翔, 张宜凡, 杜望春, 陈群力, 姚虹, 赵梅. 天然产物通过调节活性氧水平防治肿瘤的研究进展[J]. 中国药学(英文版), 2021, 30(6): 455-467.
[8]	王惊雷, 宋柯, 潘昊, 刘洋, 王大壮, 陈立江. 纳米药物在肿瘤治疗中的现状和挑战[J]. 中国药学(英文版), 2021, 30(5): 359-380.
[9]	宋慧慧, 向卓, 薛淑一, 苗青, 赵丽艳, 李明春. 白头翁皂苷及其单体抗肿瘤作用及机制的研究进展[J]. 中国药学(英文版), 2021, 30(5): 381-392.
[10]	雍灵, 姚烨, 韩梦仪, 严晓雪, 姚庆宇, 郭昱辰, 薛钧升, 陈国术, 周田彦. QAP21抑制转移性乳腺癌细胞的干性和运动能力[J]. 中国药学(英文版), 2021, 30(4): 289-305.
[11]	刘曼, 张爽, 李卓越, 王光雪, 王景茹, 张烜. 氧化锌纳米粒的制备与表征[J]. 中国药学(英文版), 2020, 29(9): 617-625.
[12]	周楚杭, 胡新平, 刘琦, 王乐淇, 周远航, 靳尧, 刘艳. 增强抗肿瘤药物肿瘤靶向性递送的叶酸修饰的pH敏感聚合物胶束[J]. 中国药学(英文版), 2020, 29(9): 626-636.
[13]	北京大学药学院. 2020年张强教授团队在靶向递药领域获系列进展[J]. 中国药学(英文版), 2020, 29(9): 675-678.
[14]	周北斗, 俞紫涵, 童玉贵, 李佳莉, 黄堡城, 魏蓉蓉, 翁智敏, 王欣, 阮志鹏, 林健, 许彩红, 刘建波. 异戊烯基和香叶基取代的呫吨酮的合成与生物活性研究[J]. 中国药学(英文版), 2020, 29(8): 564-576.
[15]	薛钧升, 王思媛, 郝方然, 田秀云, 苏红, 杨亮, 安启明, 郝纯毅, 周田彦. 多巴胺增强舒尼替尼治疗胰腺癌的药效[J]. 中国药学(英文版), 2020, 29(10): 689-700.